Mechanism of action of GLP-1 receptor agonists

Mechanism of Action of GLP-1 Receptor Agonists

by

Introduction

GLP-1 receptor agonists are a class of antidiabetic drugs that mimic the action of glucagon-like peptide-1 (GLP-1), an incretin hormone that enhances insulin secretion in response to meals. These agents are used primarily in the treatment of type 2 diabetes mellitus and obesity. Their unique ability to improve glycemic control without causing significant hypoglycemia, along with favorable effects on weight and cardiovascular risk, makes them highly valuable in metabolic therapy.

Step-by-Step Mechanism of Action

  1. GLP-1 Receptor Activation
    GLP-1 receptor agonists bind to and activate the GLP-1 receptors, which are G-protein-coupled receptors located in pancreatic beta cells, the brain, gastrointestinal tract, and heart.
  2. Glucose-Dependent Insulin Secretion
    Activation of GLP-1 receptors enhances insulin secretion in a glucose-dependent manner, helping lower postprandial glucose levels without causing hypoglycemia.
  3. Suppression of Glucagon Secretion
    These agents reduce glucagon secretion from pancreatic alpha cells, particularly during hyperglycemia, which helps decrease hepatic glucose output.
  4. Delayed Gastric Emptying
    GLP-1 receptor agonists slow gastric emptying, leading to reduced postprandial glucose spikes and increased satiety.
  5. Appetite Suppression
    They act on the hypothalamus to reduce appetite and promote weight loss, an important benefit in patients with obesity and type 2 diabetes.
  6. Cardiovascular and Renal Effects
    Some GLP-1 receptor agonists have shown cardiovascular benefits, including reduced risk of major adverse cardiac events. They also exert nephroprotective effects by reducing albuminuria and oxidative stress.
Mechanism of action of GLP-1 receptor agonists flowchart
GLP-1 receptor agonists mechanism of action flowchart

Pharmacokinetic Parameters

ParameterValue (Varies by Agent)
RouteSubcutaneous (most), oral (semaglutide)
BioavailabilityLow (oral semaglutide ~1%)
Tmax1–4 hours (short-acting); ~24–48 h (long-acting)
Half-life2–4 h (exenatide); ~5–7 days (semaglutide)
MetabolismProteolytic degradation
ExcretionRenal (peptide degradation products)

Clinical Uses

  • Type 2 diabetes mellitus
  • Obesity management
  • Cardiovascular risk reduction in patients with diabetes
  • Nonalcoholic fatty liver disease (off-label, investigational)

Adverse Effects

  • Nausea and vomiting
  • Diarrhea
  • Pancreatitis (rare)
  • Thyroid C-cell tumors (rodent studies)
  • Injection site reactions (if injectable)

Comparative Analysis

DrugDosing FrequencyWeight Loss BenefitCV BenefitNotable Notes
ExenatideTwice dailyModerateNoShort-acting
LiraglutideOnce dailyHighYesFDA-approved for weight loss
SemaglutideOnce weekly/oralVery highYesOral and injectable forms
DulaglutideOnce weeklyHighYesEasy weekly dosing

MCQs

  1. GLP-1 receptor agonists primarily act on:
    a) Alpha cells b) Beta cells c) Delta cells d) Hepatocytes
    Answer: b) Beta cells
  2. These drugs increase insulin secretion in a:
    a) Continuous manner b) Glucose-independent way c) Glucose-dependent way d) Inhibited state
    Answer: c) Glucose-dependent way
  3. Which of the following is a known adverse effect of GLP-1 agonists?
    a) Hypoglycemia b) Bradycardia c) Nausea d) Tachycardia
    Answer: c) Nausea
  4. GLP-1 agonists help reduce weight by:
    a) Increasing insulin resistance b) Enhancing appetite c) Suppressing appetite d) Stimulating glucagon
    Answer: c) Suppressing appetite
  5. Which agent is available in oral formulation?
    a) Exenatide b) Liraglutide c) Dulaglutide d) Semaglutide
    Answer: d) Semaglutide
  6. Cardiovascular benefits of GLP-1 agonists are most evident in:
    a) Type 1 diabetes b) Type 2 diabetes with CV risk c) Healthy adults d) Children
    Answer: b) Type 2 diabetes with CV risk
  7. GLP-1 receptor agonists delay:
    a) Insulin action b) Glucose absorption c) Gastric emptying d) Renal excretion
    Answer: c) Gastric emptying
  8. Pancreatitis is a:
    a) Common effect b) Contraindication c) Rare adverse effect d) Desired action
    Answer: c) Rare adverse effect
  9. Main site of GLP-1 receptor action for appetite regulation is:
    a) Pancreas b) Liver c) Hypothalamus d) Kidney
    Answer: c) Hypothalamus
  10. Liraglutide is FDA-approved for:
    a) Anemia b) Depression c) Weight loss d) Osteoporosis
    Answer: c) Weight loss

FAQs

1. Can GLP-1 receptor agonists be used in type 1 diabetes?
Not recommended, as they rely on functional beta cells to exert their glucose-lowering effect.

2. How long does it take to see results?
Glycemic improvement is often seen within weeks; weight loss benefits take a few months.

3. Are these drugs used alone or with others?
They can be used as monotherapy or in combination with metformin, SGLT2 inhibitors, or insulin.

4. Is there a risk of hypoglycemia?
Low, unless combined with insulin or sulfonylureas.

5. Do these drugs protect the heart?
Yes, certain agents like liraglutide and semaglutide have shown cardiovascular benefits.

References

Related Links

Mechanism of Action of Amantadine

MCQ Quiz: Management of Parkinson’s Disease

Leave a Comment